Navigation Links
AcelRx Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference
Date:9/9/2011

REDWOOD CITY, Calif., Sept. 9, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at the Rodman & Renshaw Global Investment Conference in New York, NY at The Waldorf Astoria. The presentation is scheduled for Tuesday, September 13, 2011 at 1:35 p.m. ET.  

The presentation will be webcast live and can be accessed through http://www.wsw.com/webcast/rrshq20/acrx.  For those who are not available to listen to the live broadcast, the presentation will be archived and available through http://www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is in preparation for Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain that is expected to enter Phase 2 clinical development in the second half of 2011 under a grant from the US Army Medical Research and Material Command.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
2. AcelRx Pharmaceuticals Reports First Quarter 2011 Financial Results
3. AcelRx European Patent Covering its NanoTabĀ® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period
4. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
5. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
6. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
7. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
8. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
9. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
10. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
11. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... AVIV, Israel, May 29, 2017  Cellect Biotechnology Ltd. ... innovative technology which enables the functional selection of stem ... results for the first quarter ended March 31 st ... with our accomplishments in the first quarter of 2017," ... first quarter, we announced the treatment of the first ...
(Date:5/26/2017)... Calif. , May 25, 2017  In response ... States , Direct Relief is working with Pfizer ... Naloxone available at no cost to community health centers, ... nonprofit providers nationwide. "Pfizer has a ... to medicines and ensuring patient safety through educational activities," ...
(Date:5/23/2017)... 23, 2017  Leaf Healthcare, recognized for developing ... for pressure ulcer prevention, will unveil its comprehensive ... Critical Care Nurses, National Teaching Institute and Critical ... The Leaf Patient Monitoring System is the first ... environment.  The system seamlessly tracks patient movement throughout ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that puts them at ... Adam and Hal Kimowitz are currently accepting new patients at their practice for these ... for some patients, which is why they offer the latest in modern dental techniques ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... Clinical Innovation Catalyst program focused on finding product improvements that could ... placed in their throats when they need help breathing or to provide medication. ...
(Date:6/20/2017)... Ariz. (PRWEB) , ... June 20, 2017 , ... ... Natural Brands®, makers of SweetLeaf® Stevia Sweetener, Michael P. May, Ph.D., recently accepted ... Sun Corridor Export Recognition Program selected Wisdom Natural Brands (WNB), and 16 other ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... the security systems industry has been selected as the partner of choice by ... a passenger railroad service that provides medium- and long-distance intercity service in the ...
(Date:6/20/2017)... ... June 20, 2017 , ... John D'Eri, CEO of ... Leader in Adult Autism Award during the Autism Society of America 's ... The Daniel Jordan Fiddle Foundation (DJFF) was founded in 2002 as the ...
Breaking Medicine News(10 mins):